These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 27766865

  • 1. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
    Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, Cole S, Gibson KR, Jones R, Morao I, Nedderman A, Omoto K, Robinson C, Ryckmans T, Skinner K, Stupple P, Waldron G.
    J Med Chem; 2016 Nov 23; 59(22):10084-10099. PubMed ID: 27766865
    [Abstract] [Full Text] [Related]

  • 2. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.
    Bagal SK, Andrews M, Bechle BM, Bian J, Bilsland J, Blakemore DC, Braganza JF, Bungay PJ, Corbett MS, Cronin CN, Cui JJ, Dias R, Flanagan NJ, Greasley SE, Grimley R, James K, Johnson E, Kitching L, Kraus ML, McAlpine I, Nagata A, Ninkovic S, Omoto K, Scales S, Skerratt SE, Sun J, Tran-Dubé M, Waldron GJ, Wang F, Warmus JS.
    J Med Chem; 2018 Aug 09; 61(15):6779-6800. PubMed ID: 29944371
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG, Nesi M, Avanzi N, Ballinari D, Bandiera T, Bertrand J, Bindi S, Canevari G, Carenzi D, Casero D, Ceriani L, Ciomei M, Cirla A, Colombo M, Cribioli S, Cristiani C, Della Vedova F, Fachin G, Fasolini M, Felder ER, Galvani A, Isacchi A, Mirizzi D, Motto I, Panzeri A, Pesenti E, Vianello P, Gnocchi P, Donati D.
    Bioorg Med Chem; 2014 Sep 01; 22(17):4998-5012. PubMed ID: 25009002
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X, Kopecky DJ, Liu J, Liu J, Jaen JC, Cardozo MG, Sharma R, Walker N, Wesche H, Li S, Farrelly E, Xiao SH, Wang Z, Kayser F.
    Bioorg Med Chem Lett; 2012 Oct 01; 22(19):6212-7. PubMed ID: 22929232
    [Abstract] [Full Text] [Related]

  • 7. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
    Zhang Y, Liu Y, Zhou Y, Zhang Q, Han T, Tang C, Fan W.
    Bioorg Med Chem Lett; 2021 Jan 01; 31():127712. PubMed ID: 33246108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T, Lamb ML, Scott DA, Wang H, Block MH, Lyne PD, Lee JW, Davies AM, Zhang HJ, Zhu Y, Gu F, Han Y, Wang B, Mohr PJ, Kaus RJ, Josey JA, Hoffmann E, Thress K, Macintyre T, Wang H, Omer CA, Yu D.
    J Med Chem; 2008 Aug 14; 51(15):4672-84. PubMed ID: 18646745
    [Abstract] [Full Text] [Related]

  • 11. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
    Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E, Bauer SM, Schmidtkunz K, Wenzler S, Metzger E, Kuster B, Laufer S, Schüle R, Sippl W, Breit B, Jung M.
    Future Med Chem; 2016 Sep 14; 8(13):1537-51. PubMed ID: 27572962
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase.
    Kurup S, McAllister B, Liskova P, Mistry T, Fanizza A, Stanford D, Slawska J, Keller U, Hoellein A.
    J Enzyme Inhib Med Chem; 2018 Dec 14; 33(1):74-84. PubMed ID: 29115879
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L, Pei H, Zhang C, Shao M, Li D, Tang M, Wang T, Chen X, Xiang M, Chen L.
    Eur J Med Chem; 2018 Feb 10; 145():96-112. PubMed ID: 29324347
    [Abstract] [Full Text] [Related]

  • 14. Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.
    Wang Z, Ran T, Xu F, Wen C, Song S, Zhou Y, Chen H, Lu X.
    Chem Commun (Camb); 2021 Oct 12; 57(81):10588-10591. PubMed ID: 34560776
    [Abstract] [Full Text] [Related]

  • 15. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P.
    J Med Chem; 2015 Jan 08; 58(1):419-32. PubMed ID: 25353650
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y, Liu WJ, Yin L, Li H, Chen ZH, Zhu DX, Song XQ, Cheng ZZ, Song P, Wang Z, Li ZG.
    Bioorg Med Chem Lett; 2018 Mar 01; 28(5):974-978. PubMed ID: 29429832
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.